Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
about
Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.The Use of Synthetic Carriers in Malaria Vaccine DesignCationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigensBiodegradable polymeric microsphere-based vaccines and their applications in infectious diseasesBiomedical Applications of Biodegradable Polymers.The microclimate pH in poly(D,L-lactide-co-hydroxymethyl glycolide) microspheres during biodegradationFormulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.Surface characterisation of bioadhesive PLGA/chitosan microparticles produced by supercritical fluid technology.PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity.Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticlesRobust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants.Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.Strategies for intranasal delivery of vaccinesApplications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model.Peptide/protein vaccine delivery system based on PLGA particles.Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways.Chitosan-based delivery systems for mucosal vaccines.Heat shock proteins are therapeutic targets in autoimmune diseases and other chronic inflammatory conditions.Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines.Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.Applications of nanotechnology for immunology.Intranasal formulations: promising strategy to deliver vaccines.Nasal and pulmonary vaccine delivery using particulate carriers.PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.Current prospects and future challenges for nasal vaccine delivery.Dual agents loaded polymeric nanoparticle: Effect of process variablesIntranasal delivery of nanoparticle-based vaccines.Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugsDevelopment of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen.Recent developments in nanocarrier-aided mucosal vaccination.Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii.Mesoporous Silica Nanoparticle-Coated Microneedle Arrays for Intradermal Antigen DeliveryCharacterization of Inner and Outer Membrane Proteins from Francisella tularensis Strains LVS and Schu S4 and Identification of Potential Subunit Vaccine Candidates.Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine.
P2860
Q26748776-23CFA35C-3D54-4DFA-85E8-62181F1306C0Q26777053-B4E5C834-2C5C-4851-B359-2E34B4D5CA96Q27310007-75427943-A6EB-4263-A0B5-15B594B8675EQ28087409-6AE8E96C-5935-4A66-8E4C-3493E5643477Q30426452-A375C2AD-E464-4E85-8518-17D3CB4BDCEEQ31075222-EE95B56C-9CF6-4819-89CD-69A4789069EBQ33650861-5887A17C-0AD3-496E-9058-E5A325F365C3Q33843464-C1D964DC-C57E-4985-B4AB-2F1A40C659A1Q34071603-0CBA3E4A-E562-495F-80CE-B686B95E8433Q34455041-CBAC471B-DA7F-43AE-9664-FAB9793F9A66Q34661842-7C541318-0D17-48B1-B66A-0D405C1E34F1Q35199270-C5A4AD32-085C-41FC-A34C-62E2EEC86BADQ35593603-01D765C8-797A-47C3-8BA5-247C883F8ACBQ35997275-54B6A4F1-5D34-4CA8-A108-5E6690400345Q36514771-BAC36C0E-DAB7-45A9-98F7-45577404FA96Q36591050-753AE2F1-436C-4A1A-9568-5AE6E4075931Q36714034-88570F81-4F98-4A0C-AA79-61FEC423ED88Q37575958-8A4A279F-422F-41FA-8E2A-273E9FA57EADQ37838652-9C6DED52-30C3-4A12-91B9-9D5380DFBB4DQ37862470-1DC3BEB2-626A-40A6-84D5-005BA358AB63Q38019583-AD8B375A-AFEB-4E04-A641-F735986A95A8Q38026064-9DFA6F67-C3B9-4AFD-92BD-7A692494585EQ38031950-4F279356-9935-411C-B3F3-E8656F130578Q38066148-F30B13AD-CF74-43D6-85FB-673726C03918Q38123937-C0AB11D7-B428-455F-8A5F-2B751DCA7D27Q38223050-B01A51C9-E31A-4AD9-AC3A-C82FD7EE7440Q38465267-80B0163E-ABB9-42CB-AF3D-DF2E55D7444DQ38692217-8412AFFA-77E3-477E-BFF0-A8B6173CFBA2Q38784950-7D5918C2-B0CF-44AB-9FC0-39244F656CB5Q38844946-BE1A6205-6DD3-45A9-B81B-05409D1DA0F6Q39113247-E95F5FD9-0A3A-4C96-8CDE-2C343F3AE5B3Q39161562-BDAEF9D7-E633-485D-B9E5-D0F3C4BF7E61Q39897426-496806B3-FC9D-42AE-9112-10D048B307D0Q39961868-39DE1D3F-4C08-476A-86CE-0026179421C8Q40228907-480C329E-6DD5-4CF4-8E71-51814CFD70A8Q40482585-5168FC43-B427-44A6-B748-3439A371FFA3Q40956743-DD685DDB-FF9A-46DB-ABC1-AAA18C3DCD9EQ41987534-0380EDAC-E085-4A59-B9A7-CD02CFBA9DC2Q48938733-CAF8EEF1-432D-4E2F-A591-3687DB423541Q49387538-4C44A161-8D27-4BA4-B923-01A52BAE946B
P2860
Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Nasal vaccination with N-trime ...... inst the encapsulated antigen.
@en
Nasal vaccination with N-trime ...... inst the encapsulated antigen.
@nl
type
label
Nasal vaccination with N-trime ...... inst the encapsulated antigen.
@en
Nasal vaccination with N-trime ...... inst the encapsulated antigen.
@nl
prefLabel
Nasal vaccination with N-trime ...... inst the encapsulated antigen.
@en
Nasal vaccination with N-trime ...... inst the encapsulated antigen.
@nl
P2093
P50
P1433
P1476
Nasal vaccination with N-trime ...... inst the encapsulated antigen.
@en
P2093
Bram Slütter
Chantal Keijzer
Clemens Löwik
Eric Kaijzel
Joke Bouwstra
Niels Hagenaars
Roel Mallants
Wim Jiskoot
P304
P356
10.1016/J.VACCINE.2010.06.121
P407
P577
2010-07-16T00:00:00Z